2003 (v1)
Publication
No description
Uploaded on: March 27, 2023
-
-
2019 (v1)Publication
High risk Neuroblastoma (NB) includes aggressive, metastatic solid tumors of childhood. The survival rate improved only modestly, despite the use of combination therapies including novel immunotherapies based on the antibody mediated targeting of tumor-associated surface ligands. Treatment failures may be due to the lack of adequate in vitro...
Uploaded on: April 14, 2023 -
1992 (v1)Publication
No description
Uploaded on: March 31, 2023 -
2023 (v1)Publication
Natural killer (NK) cell-based adoptive immunotherapy in leukemia patients is an emerging field of interest based on clinical evidence of efficacy and safety. Elderly acute myeloid leukemia (AML) patients have been successfully treated with NK cells from HLA-haploidentical donors, especially when high amounts of alloreactive NK cells were...
Uploaded on: February 6, 2024 -
2022 (v1)Publication
Natural killer (NK) cells represent a promising cell type in antitumor immunotherapy for efficacy and safety, particularly in the treatment of hematologic malignancies. NK cells have been shown to exert antileukemia activity in the context of haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Products have been developed to...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
NK cells can exert remarkable graft-versus-leukemia (GvL) effect in HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Here, we dissected the NK-cell repertoire of 80 pediatric acute leukemia patients previously reported to have an excellent clinical outcome after αβT/B-depleted haplo-HSCT. This graft manipulation strategy...
Uploaded on: April 14, 2023